HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
pu4nTBwYsPY0J3tz